News

January 19, 2018January 19, 2018

Vitality Biopharma Seeks FDA’s Orphan Drug Status for Cannabinoid Therapy VITA-100

News

Vitality Biopharma is seeking orphan drug designation from the U.S. Food and Drug Administration (FDA) for its targeted cannabinoid therapy, VITA-100, for the treatment of pediatric ulcerative colitis. The FDA grants orphan ... Read more

January 18, 2018

Researchers Identify Immune Cells That May Prevent Fungal Initiation of IBD

News

Researchers at Weill Cornell Medicine in New York suggest an impaired immune regulation of gut fungi may cause inflammatory bowel disease (IBD). The study, “CX3CR1+ mononuclear phagocytes control immunity to intestinal fungi,” appeared ... Read more

January 17, 2018

FDA to Review Sandoz’s Application for Biosimilar to Bowel Disease Therapy Humira

News

The U.S. Food and Drug Administration has agreed to review Sandoz’s application for a biosimilar to AbbVie’s bowel disease therapy Humira (adalimumab). “When patients are dealing with a chronic disease, it is imperative ... Read more

January 16, 2018January 16, 2018

LRRK2 Gene May Link Crohn’s and Parkinson’s Among Ashkenazi Jews, Study Finds

News

Ashkenazi Jews with Crohn’s disease are more likely to have mutations on the LRRK2 gene — a known cause of inherited Parkinson’s disease — say researchers with the Icahn School of Medicine at ... Read more

January 15, 2018

FDA OKs Application for Immunic’s UC Therapy, Green-lighting Phase 2 Trial

News

The U.S. Food and Drug Administration has cleared the way for Immunic Therapeutics to begin a Phase 2 trial testing IMU-838, its therapy candidate for ulcerative colitis. The FDA’s approval of Immunic’s investigational new drug ... Read more

January 12, 2018

Protagonist Obtains Third Patent for Therapy Targeting a Bowel Disease-related Protein

News

Protagonist Therapeutics has obtained a U.S. patent for an inflammatory bowel disease treatment that is in clinical trials. PTG-100 inhibits a protein known as alpha-4-beta-7 integrin that is associated with IBDs. Scientists consider it one ... Read more

January 11, 2018

Vitality Biopharma Unveils Cannabis-based Potential Bowel Disease Therapy

News

Vitality Biopharma has developed a cannabis-based potential treatment for inflammatory bowel diseases. Its annoucement about VITA-100 comes as U.S. regulators have been approving cannabis-based products for various disorders. VITA-100 delivers two of the active ... Read more

January 10, 2018January 10, 2018

Phase 1 Results Support Development of TopiVert Therapy for Ulcerative Colitis

News

Positive safety data from a Phase 1 trial supports TopiVert’s continued development of TOP1288 to treat ulcerative colitis, the British pharma company announced. TOP1288 targets several important enzymes including P38, Src, Lck and ... Read more

January 9, 2018January 9, 2018

FDA Clears First Fully Automated Calprotectin Test for IBD Diagnosis, Inova Says

News

The U.S. Food and Drug Administration (FDA) has approved the QUANTA Flash Calprotectin test to help diagnose inflammatory bowel disease (IBD) and differentiate that disease from irritable bowel syndrome (IBS). Developed by ... Read more

January 8, 2018January 8, 2018

Belgium Approves Extension Trial of Abivax’s Ulcerative Colitis Therapy

News

Regulators in Belgium have approved Abivax’s request for a long-term extension of the company’s ongoing Phase 2a trial of ABX464 as a treatment for ulcerative colitis. It said it expects approvals from ... Read more